SCHEMBL6988205

SCHEMBL6988205

O=C(O)c1nc2cccc(F)c2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.42
PIN1 Q13526 2/20 0.41
PCSK9 Q8NBP7 1/20 0.40
POLB P06746 1/20 0.40
TTR P02766 1/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
DAO P14920 2/20 0.39
DDO Q99489 1/20 0.39
DYRK3 O43781 1/20 0.39
DYRK2 Q92630 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
PARP1 P09874 1/20 0.38
ALB P02768 1/20 0.38
DHODH Q02127 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RAB9A P51151 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28945197 0.88 PCSK9 (0.47) DYRK1APCSK9POLBCA12CA9
SCHEMBL7647 0.81 PIN1 (0.42) DYRK1APIN1CA12CA9DYRK2
SCHEMBL8952892 0.81 ALDH1A1 (0.47) PIN1DHODHALDH1A1MAPTRAB9A
SCHEMBL30310472 0.79 DYRK1A (0.51) DYRK1APIN1CA12CA9DAO
SCHEMBL6961429 0.79 PIN1 (0.41) DYRK1APIN1POLBDYRK2DYRK1B
SCHEMBL7706759 0.79 DYRK1A (0.51) DYRK1APIN1CA12CA9DAO
SCHEMBL1144716 0.79 PIN1 (0.49) PIN1DAODDOPARP1ALDH1A1
SCHEMBL11047670 0.79 PIN1 (0.41) DYRK1APIN1DYRK2DYRK1BALDH1A1
SCHEMBL31568926 0.79 PIN1 (0.39) DYRK1APIN1POLBDYRK2DYRK1B
SCHEMBL38664289 0.79 POLB (0.43) DYRK1APOLBCA12CA9DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024107778-A1 NOVEL PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-23 WO disclosed
US-9718803-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. (US) 2017-08-01 US disclosed
US-20160102075-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2016-04-14 US disclosed
US-8957073-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. 2015-02-17 US disclosed
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2011-12-15 US disclosed
WO-2011143365-A1 NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2011-11-17 WO disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102075-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A DYRK1A 4063/4885PIN1 315/4885PCSK9 1226/4885
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A DYRK1A 4063/4885PIN1 315/4885PCSK9 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.